The government’s medical science/medicines watchdog is to begin talks with venture capitalists to discuss which experimental treatments would be most likely to be bought by the National Health Service.
The National Institute of Health and Clinical Excellence (Nice), which recommends whether the NHS should buy new medicines, plans a meeting this autumn with several groups that fund early-stage drug research.
The approach could strengthen the UK’s life sciences sector, helping funders direct money into experimental treatments with the greatest chance to be ultimately judged cost effective – as well as merely biologically efficacious.
It follows consultations between the agency and pharmaceutical companies since 2008, under which drug developers have discussed and modified the way that they conduct their late-stage clinical trials to ensure Nice has the information it seeks to best judge cost-effectiveness.
The primary role of Nice, established in 1999, remains to make a judgment on whether prices already set by companies on new medicines represent good value for the NHS, or would instead unjustifiably squeeze other more effective medical spending.
Read the full article at the Financial Times
Read: more on dealtalk in pharma, biotech, life science partnering deal news, insights and glossary
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity